Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam
Open Access
- 1 December 2009
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (12) , 2305-2313
Abstract
CYP3A4 is an important determinant of drug-drug interactions. In this study, we evaluated whether cytochrome P450 3A knockout mice [Cyp3a(−/−)] and CYP3A4 transgenic (CYP3A4-Tg) mice can be used to study drug-drug interactions in the liver and intestine. Triazolam was used as a probe drug because it is a highly specific CYP3A substrate and not a P-glycoprotein substrate. Triazolam metabolism was profoundly reduced in Cyp3a(−/−) mice both in vitro and in vivo. In vitro studies revealed clear species differences in humans and mice, but triazolam metabolism in microsomes derived from CYP3A4-Tg “humanized” mice closely resembled that in human microsomes. It is interesting to note that studies with tissue-specific CYP3A4-Tg mice revealed that intestinal CYP3A4 has a major impact on oral triazolam exposure, whereas the effect of hepatic CYP3A4 was limited. To mimic a drug-drug interaction, we coadministered triazolam with the prototypical CYP3A inhibitor ketoconazole, which increased triazolam exposure in all the CYP3A-proficient mouse strains but not in Cyp3a(−/−) mice. We further found that the anticancer drug gefitinib is a potent stimulator of 1′-OH triazolam formation in vitro. It is noteworthy that we could also show in vivo stimulation of triazolam metabolism by gefitinib, resulting in a lower oral triazolam exposure. To our knowledge, this is the first in vivo example of direct stimulation of CYP3A4 activity after oral drug administration. Overall, this study illustrates how Cyp3a(−/−) and CYP3A4-Tg mice can be used to study drug-drug interactions. The data clarify that for drugs that are not P-glycoprotein substrates, intestinal metabolism also can be more important than hepatic metabolism after oral administration.Keywords
This publication has 33 references indexed in Scilit:
- Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liverThe FASEB Journal, 2008
- Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C EnzymesMolecular Pharmacology, 2008
- Gut instincts: CYP3A4 and intestinal drug metabolismJournal of Clinical Investigation, 2007
- Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolismJournal of Clinical Investigation, 2007
- Structural basis for ligand promiscuity in cytochrome P450 3A4Proceedings of the National Academy of Sciences, 2006
- GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECANDrug Metabolism and Disposition, 2005
- Cytochrome P450-dependent metabolism of gefitinibXenobiotica, 2005
- The Mucosa of the Small IntestineClinical Pharmacokinetics, 2002
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Cooperativity in Oxidations Catalyzed by Cytochrome P450 3A4Biochemistry, 1997